Transcode Therapeutics (RNAZ) Receivables - Other (2025 - 2026)

Transcode Therapeutics' (RNAZ) quarterly Receivables - Other came in at $638.0 in Q1 2026, little changed on a QoQ basis from $638.0 in Q4 2025.

Transcode Therapeutics (RNAZ) Receivables - Other (2025 - 2026) Analysis & Trends

Transcode Therapeutics (RNAZ) has 2 years of Receivables - Other data on file, last reported at $638.0 in Q1 2026.

Quarterly Receivables - Other changed N/A year-over-year to $638.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $638.0 (changed N/A YoY) and the FY2025 annual result came in at $638.0, changed N/A from the prior year.
Receivables - Other held at $638.0 in Q1 2026, from $638.0 in the prior quarter.
In the past five years, Receivables - Other ranged from a high of $638.0 in Q4 2025 to a low of $638.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.41 Bn	131.56 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.14 Bn	78.15 Bn	3.93 Bn
3	Argenx Se	65.52 Bn	60.34 Bn	1.37 Bn
4	Moderna	58.21 Bn	53.07 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.05 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn
7	BioNTech SE	27.95 Bn	9.56 Bn	668.28 Mn
8	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
9	Royalty Pharma	27.30 Bn	26.46 Bn	-
10	Transcode Therapeutics	2.84 Mn	2.84 Mn	-

Download Data